Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.4174/astr.2021.100.3.127
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2021
- Creator
-
Park, Kyoung Sik
Saindane, Madhuri
Yang, Eun Yeol
Jin, TongYi
Rallabandi, Harikrishna Reddy
Heil, Alexander
Nam, Sang Eun
Yoo, Young Bum
Yang, Jung-Hyun
Kim, Jong Bin
Park, Seo-Young
Park, Won Seo
Youn, Yeo-Kyu
- DOI
-
10.18154/RWTH-2021-03255
- URN
-
urn:nbn:de:101:1-2021060303231753647399
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Park, Kyoung Sik
- Saindane, Madhuri
- Yang, Eun Yeol
- Jin, TongYi
- Rallabandi, Harikrishna Reddy
- Heil, Alexander
- Nam, Sang Eun
- Yoo, Young Bum
- Yang, Jung-Hyun
- Kim, Jong Bin
- Park, Seo-Young
- Park, Won Seo
- Youn, Yeo-Kyu
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2021
Other Objects (12)
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option